N-Acetyl Selank Amidate: what the studies show, status and safety
Summary
N-Acetyl Selank Amidate is Selank, a peptide licensed as a medicine in Russia, with a small chemical cap added at each end. Searches of eight databases, each checked against a control search for Selank, found no test of this modified form in cells, animals or people. The only scientific paper found that names it lists it as a reference sample for a Belgian drug-testing method. No approval was found in any market checked, and no database record of its own. Everything claimed about its effects is borrowed from Selank, and it is banned in sport at all times.
Key findings at a glance
- One paper, and it is about testing, not effects. A Belgian medicines control laboratory used the molecule as a reference sample for a drug-screening method published in 2020. The paper holds no biological data [1].
- No study found in cells, animals or people. Eight literature, substance and trial databases were searched on 23 September 2026. The same PubMed run found 136 records for Selank, so the search itself works [2], [3], [4].
- No database record of its own found. The PubChem entry and the American substance code that appear under "N-acetyl selank" belong to a different molecule, one that is acetylated only [5], [6], [7].
- On sale since at least 2015. An archived shop page from 8 October 2015 offers the amidated form. For information it sends buyers to the encyclopaedia article about Selank [8].
- An American register entry mixes up the names. A bulk listing called "Selank Acetate" gives its active ingredient as "N-ACETYL SELANK", which is a different molecule [9].
- The Russian licence covers Selank only. All 20 records found in the Russian state register concern Selank itself. None contains the modified molecule [10].
- Clearly banned in sport. No approval was found in any market checked, so category S0 of the 2026 Prohibited List applies. For Selank itself that question is still open [11].
What it is
N-Acetyl Selank Amidate is a trade name, not a scientific or official one. It describes Selank with two small chemical changes. Selank is a chain of seven amino acids, the building blocks of proteins, licensed as nasal drops in Russia. Its full story is on the Selank page.
The first change is an acetyl group, a small chemical cap, attached to the start of the chain. The second turns the acid at the end of the chain into an amide.
Sellers present the changes as protection against breakdown in the body [12]. No published paper found explains why the two were combined, and no laboratory or company was found to claim the molecule [2], [13].
Quick facts
| Field | Value | Ref |
|---|---|---|
| What it is sold as | A modified form of Selank, with no scientific or regulatory standing | [1] |
| Sequence | Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2, short form Ac-TKPRPGP-NH2 | [1] |
| Formula | C35H60N12O9 | [1] |
| Mass | 792.94 g/mol, calculated; 792.4606 Da for the most common isotope form | [1] |
| Parent substance | Selank, PubChem CID 11765600 | [5] |
| PubChem entry | None found. A search by structure returned no record | [5] |
| American substance code (UNII) | None found. The code J3PM702O93 belongs to the acetylated-only form | [7], [13] |
| CAS registry number | None found | [5] |
| How long it lasts in the body | No published value found | [2] |
| Registered studies in people | None found | [4] |
| Approval status | No approval found in any market checked | [10], [14] |
Three molecules, easily confused
| Form | Sequence | Formula | Molar mass | Database record |
|---|---|---|---|---|
| Selank | TKPRPGP | C33H57N11O9 | 751.89 g/mol | PubChem CID 11765600, UNII TS9JR8EP1G [5], [7] |
| N-acetyl selank, acetylated only | Ac-TKPRPGP-OH | C35H59N11O10 | 793.92 g/mol | PubChem CID 133082488, UNII J3PM702O93 [6], [13] |
| N-Acetyl Selank Amidate | Ac-TKPRPGP-NH2 | C35H60N12O9 | 792.94 g/mol | None found [5], [7] |
The two modified forms differ by less than one mass unit, and their names differ by one word. That matters below, because a label reading "N-acetyl selank" does not say which of the two is meant.
How it works
This is unknown. No study found has tested what this molecule does in a cell, an animal or a person [2], [3], [4]. What circulates instead are claims made by sellers, and each can be traced to its origin.
- "Capping both ends makes it more stable." No stability measurement was found for this molecule, nor for the acetylated-only form [2], [3].
- "The acetyl cap carries it into the brain faster." A seller made this claim in 2015 for the acetylated-only form, without citing any study [12]. No such measurement was found for any Selank derivative [2].
- "It calms anxiety, eases stress and sharpens memory." These are findings about Selank, carried over to a different molecule. Even for Selank, the human evidence is thin, as its own page sets out.
One detail shows why carrying findings over does not work. In the blood, Selank is cut into smaller pieces, some of which are thought to contribute to its effects. The acetyl cap changes the first of those pieces and the amide changes the last. Whether the variant produces the same pieces at all is unknown.
The sibling product N-Acetyl Semax Amidate follows the same naming pattern and raises the same questions.
What the trials found
No trials were found. The searches found no registered or published study in people and no animal or cell experiment. The only scientific paper found that names the molecule is about detecting it, not about what it does [1], [4].
The one paper that names it
Analytical only In 2020, Sciensano, the Belgian public health institute, published a method for detecting 10 peptides offered online as brain enhancers, so-called nootropics. N-Acetyl Selank Amidate was one of the reference samples, listed separately from acetylated-only Selank and from Selank itself [1].
The samples were made to order with a purity above 95 per cent. In the laboratory, the amidated form passed through the separation column in 4.94 minutes. Its main ion appeared at m/z 397.237, a mass-to-charge value [1].
The paper also examined two seized preparations. The one from the end of 2017 contained unmodified Selank, the one from 2018 Semax. Neither contained the amidated variant [1]. The authors note that using these research peptides in people has not been approved in the European Union [1].
How the absence was checked
Each search was run alongside a control search for Selank, which is known to be well recorded. An empty result therefore means that nothing was found under that name, not that the search failed.
PubMed searches run on 23 September 2026. The control term Selank returns 136 records in the same run; every search for the acetylated forms returns none. Source [2].
- PubMed. Every spelling of the name and the short sequence returned 0 records. Combined searches for Selank with amide or acetyl returned four records, and all four concern plain Selank or experiments with acetylcholine, a nerve messenger. The control term Selank returned 136 [2].
- Europe PMC, including full texts. Ten spellings returned nothing. The few hits for Selank combined with "acetylated" or "amidated" were all misses, mostly papers listing unmodified Selank. The control returned 81 [3].
- PubChem. Four names returned "not found", and a search by chemical structure found no record. A formula search returned 15 compounds, none of them related to Selank [5].
- FDA substance register. The search "selank amidate" returned 0 entries. The control "selank" returned 3, none of them the amidated form [7].
- ClinicalTrials.gov. Three searches returned 0 studies. The control returned 2, and neither involves giving Selank [4].
- Russian-language literature. All hits in the CyberLeninka library were misses. The control "селанк" returned 160 [15].
- Wikidata and patents. The Wikidata search returned no entry [16]. The only patents linked in PubChem belong to the acetylated-only form: seven documents from one applicant on delivery systems for genetic material. No study of the molecule was identified in them, although how they mention it could not be checked [17].
One limit applies. Europe PMC does not seem to index the full text of the Belgian paper. Its searches therefore cannot see names that appear only in the paper's tables [3].
What is still unknown
- Whether the molecule does anything at all in the body.
- How much reaches the bloodstream or the brain, and how long it stays.
- How the body breaks it down, and into which pieces.
- Whether it is toxic to any organ, in the short or the long term.
- Whether the two chemical caps preserve, strengthen or abolish Selank's properties.
Side effects and safety
No side-effect profile could be found, and that is not the same as being well tolerated. No published study was found in which people or animals received the molecule, so nothing has been recorded. No animal toxicology, no measurement of uptake and no human report of any kind were found [2], [4].
The clearest risk is identity. Three different things travel under similar names. Selank acetate is a salt of plain Selank. N-acetyl selank is a chemically changed molecule, and N-Acetyl Selank Amidate is changed twice [6], [9].
Even a laboratory struggles to tell the two modified forms apart. Their masses differ by 0.98 Da, and their main ions sit only 0.49 m/z apart. Separating them needs a high-resolution instrument or the separation time, 4.94 against 5.47 minutes [1].
The closest official assessment concerns the parent substance. For Selank acetate, the American regulator writes: "Compounded drugs containing selank acetate may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA lacks important information regarding any safety issues raised by selank acetate administered to humans." [18]
Immunogenicity means the risk of an immune reaction against the substance. That assessment covers Selank acetate. No assessment of the amidated variant was found [18].
What is missing
- No toxicology of any kind, including effects on fertility, genes or long-term organ health.
- No data on uptake, breakdown, half-life or entry into the brain.
- No data on immune reactions or on interactions with medicines.
- No human data of any kind.
- No pharmacopoeia standard and no approved quality specification was found, so there is no agreed test for what a vial should contain.
Why this page lists no doses
Every dose in this register comes from a published study, with the population, the length of treatment and the source attached. No study of N-Acetyl Selank Amidate was found, so there is no study dose to report [2], [4].
Doses of Selank cannot be carried over either. Selank is a different molecule and a licensed medicine in Russia, and its own page lists no doses for that reason [10]. Amounts on sales pages come from sales copy rather than measurement, so they are not repeated here.
Development and approval status
A shop product beside a licensed medicine
- 2009Selank licensed in RussiaNasal drops for the parent peptide, not for this variant, ref [10]
- June 2015Acetylated Selank on sale onlineEarliest archived page of an American shop, ref [12]
- October 2015The amidated form appearsArchived product page with no data of its own, ref [8]
- February 2016French regulator reports acetylated SelankCited in the FDA substance record for the acetylated-only form, ref [13]
- August 2017Manufacturer confirms supply without prescriptionAnnouncement citing a health ministry decision, for Selank only, ref [19]
- 2020Belgian laboratory adds it as a reference sampleAnalytical method only, no biological data, ref [1]
- 23 September 2026Registers and databases searchedNo approval, study or record of its own found, refs [2], [10]
No development of N-Acetyl Selank Amidate was found. The searches found no sponsor, institute or programme, and not even the published animal experiment that substances called preclinical usually have behind them [4], [2].
- June 2015 an American online shop offers acetylated Selank, according to the earliest archived copy of its page [12].
- October 2015 the same shop lists the amidated form. The page makes no claims of its own and refers readers to the encyclopaedia article on Selank [8].
- February 2016 the French medicines regulator reports acetylated Selank, as recorded in the American substance register [13].
- 2020 the Belgian screening method includes the amidated form as a reference sample [1].
- August 2020 an American bulk listing named "Selank Acetate" starts, with "N-ACETYL SELANK" given as its active ingredient [9].
| Market | Status | Note | Ref |
|---|---|---|---|
| Russia | Not registered | Licence covers Selank only | [10] |
| United States | Not approved | No listing of the amidated form found | [9], [20] |
| European Union | Not approved | No entry in the European medicines dataset | [14] |
| Germany | Not approved | No EU approval; national database not queried | [14] |
| United Kingdom | Not approved | No authorisation found | [14] |
| Australia | Not approved | Not named in the Poisons Standard | [21] |
| Canada | Not approved | Ingredient database returns nothing | [22] |
| Switzerland | Not approved | Not in the list of authorised medicines | [23] |
The entries were checked on 23 September 2026, with a control search wherever a database could be queried. Semaglutide returned 10 European, 51 Canadian and 17 Swiss entries; BPC-157 appears 3 times in the Australian Poisons Standard [14], [22], [23], [21].
Three entries rest on narrower checks. The British finding is inferred, because the regulator's database could not be queried automatically. For Germany, no European approval was found, and no national database was queried. Not being named in the Australian Poisons Standard is not permission, since unregistered medicines may not be supplied there [14], [21].
Russia needs the most care. All 20 records in the state register concern Selank from the Moscow manufacturer AO INPZ Peptogen, and none contains an acetyl or amide group [10]. The licensed medicine contains Selank as a diacetate, a salt of the unmodified peptide [24].
Selank is sold there without a prescription. On 2 August 2017 the manufacturer announced, citing a health ministry decision, that the nasal drops are dispensed in pharmacies without a doctor's prescription, under the headline that Selank "has become" a non-prescription medicine [19]. The register shows only the current status, so the status before that announcement could not be checked there [10], [24].
None of this extends to the variant. A licence belongs to one specific active substance, and the modified molecule has a different formula and mass. It is not a cheaper or newer form of the Russian medicine, and no registration of it was found [10], [1].
In the United States, nine bulk listings mention Selank, and none names the amidated form. The FDA list of bulk substances that may pose significant safety risks names Selank acetate, not the variant [9], [18]. The general picture is under are peptides legal.
Anti-doping
N-Acetyl Selank Amidate is banned at all times, in and out of competition. Category S0 of the 2026 Prohibited List covers "any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use" [11].
The variant is not named on the list, and nothing suggests that another section covers it. No approval of it was found in any market checked, so the clause applies without room for interpretation. All S0 substances count as specified substances, a technical category that affects how sanctions are handled [11].
This is where it differs from its parent. Selank holds a current Russian licence, so whether S0 covers Selank is genuinely open, as its own page explains. That licence does not protect the variant, because it is a different substance.
In Germany the variant is not named in the annex to the Anti-Doping Act [25]. The Belgian detection method is designed for drug samples, not for urine or blood [1]. The wider picture is at peptides banned in sport.
Compared with related peptides
Retention times of three reference samples in the same laboratory method, Sciensano, published 2020. The amidated form separates from the acetylated-only form by about half a minute. Source [1].
| Substance | What it is | Biological studies | Approval | Anti-doping |
|---|---|---|---|---|
| Selank | Parent peptide of seven amino acids | Published, in animals and people | Licensed in Russia only [10] | Unresolved [11] |
| N-acetyl selank | Selank with an acetyl cap only | None found [2] | None found | S0 [11] |
| N-Acetyl Selank Amidate | Selank capped at both ends | None found [2] | None found [10] | S0 [11] |
| N-Acetyl Semax Amidate | Semax capped at both ends | None found | None found | S0 [11] |
| Adamax | Shop product said to derive from Semax | None found | None found | S0 [11] |
The comparison is not about strength. It shows how far a trade product can sit from the licensed medicine whose name it borrows. Selank has a formula, a record, a register entry and a body of research that anyone can check. For the amidated variant, only analytical data from one laboratory were found.
The Semax sibling is the closest parallel. The same Belgian paper includes both amidated variants as reference samples [1]. The Selank variant is the thinner case of the two, because no biological study was found even for its acetylated-only form [2], [3].
Common misconceptions
- "It is an improved Selank that shares its research and licence." The Russian licence and the human studies concern Selank only. The variant has a different formula, and no register searched lists it as an active substance [10], [1].
- "Selank acetate is N-acetyl selank." Acetate names a salt of plain Selank. N-acetyl means a cap bonded to the chain, which makes another molecule. One American bulk listing mixes up exactly these two names [9].
- "N-acetyl selank and the amidate are the same." They differ in formula, mass and separation time, 5.47 against 4.94 minutes. A database record was found only for the acetylated-only form [1], [6].
- "The FDA code for N-acetyl selank shows official recognition." A UNII is only an identifier in a substance register. This one rests on a French regulator's report from 2016 and a seller's product page, and covers the acetylated-only form [13].
- "The PubChem record lists the correct sequence." One synonym in the PubChem and FDA records has six building blocks instead of seven. The structure in the same records has seven [6], [13].
- "If Selank may be allowed in sport, so is the variant." The opposite holds. No approval of the variant was found in any market checked, so it falls under S0 [11].
Frequently asked questions
Are there any studies on N-Acetyl Selank Amidate?
Not on what it does. The only scientific paper found that names it is a 2020 Belgian method for detecting peptides sold online, which used the molecule as a reference sample. Searches on 23 September 2026 found no study in cells, animals or people, while the same PubMed run found 136 records for Selank.
Is N-Acetyl Selank Amidate the same as Selank?
No. It is Selank with a chemical cap at each end, which gives it a different formula and a different mass. Findings about Selank, including its Russian licence and its human studies, therefore say nothing about the variant.
Is N-Acetyl Selank Amidate approved in Russia like Selank?
No. All 20 records in the Russian state register concern Selank itself, and none contains the modified molecule. Selank is sold there without a prescription, as the register and a 2017 announcement by its manufacturer confirm. Neither the licence nor that status extends to the variant.
What is the difference between N-acetyl Selank and N-Acetyl Selank Amidate?
The first carries only an acetyl cap at the start of the chain; the second is also changed at the end. Their masses differ by less than one unit, so even a laboratory needs a high-resolution instrument to tell them apart. A PubChem record was found only for the acetylated-only form.
Is Selank acetate the same as N-acetyl Selank?
No. Selank acetate is a salt of plain Selank, the form used in the Russian medicine and named on an FDA safety list. N-acetyl Selank is a chemically changed molecule. One American bulk listing uses the first name and gives the second as its ingredient, which shows how easily the two are confused.
Who invented N-Acetyl Selank Amidate?
No university or company was found to claim it. The earliest trace found is the range of an American online shop, which listed the acetylated form by June 2015 and the amidated form by October 2015. The product page for the amidated form referred buyers to the encyclopaedia article on Selank rather than to any data of its own.
Is N-Acetyl Selank Amidate banned in sport?
Yes, at all times, in and out of competition. Category S0 of the 2026 Prohibited List covers substances that no health authority has approved for use in people, and no approval of this one was found in any market checked. For Selank itself, which holds a Russian licence, the question is still open.
Is N-Acetyl Selank Amidate safe?
That cannot be answered. No toxicology, no study in animals or people and no report of side effects were found, so nothing has been recorded either way. The American regulator lacks important safety information even for Selank acetate, and no assessment of the variant was found.
Why does this page list no doses for N-Acetyl Selank Amidate?
Because no study of it was found, so there is no study dose to report. Doses of Selank cannot be carried over, since Selank is a different molecule and a licensed medicine in Russia. Amounts on sales pages are sales copy, not measurements, and are not reproduced here.
Sources
- Vanhee C, Francotte A, Janvier S, Deconinck E (2020). The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations: an incentive for controlling agencies to prepare for future encounters of the kind. Drug Testing and Analysis 12(3):371-381. PMID 31667971. DOI 10.1002/dta.2717. Table 1 lists N-acetyl selank amidate (Ac-TKPRPGP-NH2, C35H60N12O9, 792.4606 Da, retention time 4.94 min, ion m/z 397.237), N-acetyl selank (793.4446 Da, 5.47 min, m/z 397.729) and Selank (751.4341 Da, 5.25 min, m/z 376.724). The paper contains no biological data. https://sciensano.be/sites/default/files/dta_nootropic_peptides.pdf
- PubMed, NCBI E-utilities. Searches for "N-acetyl selank", "N-acetylselank", "Ac-TKPRPGP" and "acetyl selank" (0 records each); the sequence combined with acetyl or amide terms (0); Selank combined with amide terms (2 records, PMID 14552529 and 12449836, both on unmodified Selank) and with acetyl terms (2 records, PMID 37677054 and 16193654, both involving acetylcholine); control search "selank" (136 records). Retrieved 23 September 2026. https://pubmed.ncbi.nlm.nih.gov/?term=selank
- Europe PMC, REST search including full texts. Ten spellings of the modified forms, among them "N-acetyl selank amidate", "Ac-TKPRPGP-NH2" and "NA-Selank" (0 records each); Selank combined with "amidated" (1) or "acetylated" (4), all misses on checking; control "selank" (81). The full text of the Belgian paper appears not to be indexed. Retrieved 23 September 2026. https://www.ebi.ac.uk/europepmc/webservices/rest/search
- ClinicalTrials.gov, API v2. Searches for "N-acetyl selank", "NA-Selank" and "selank amidate" (0 studies each); control "selank" (2 studies, NCT01747200 and NCT05832060, neither involving Selank). Retrieved 23 September 2026. https://clinicaltrials.gov/api/v2/studies
- PubChem, PUG-REST. Name searches for "N-acetyl selank amidate", "NA-Selank amidate", "Ac-TKPRPGP-NH2" and "selank amidate" (not found each); structure search for the amidated form (no record); formula search C35H60N12O9 (15 compounds, none related to Selank); control "selank" resolving to CID 11765600. Retrieved 23 September 2026. https://pubchem.ncbi.nlm.nih.gov/compound/11765600
- PubChem. Compound CID 133082488, "N-Acetyl selank", C35H59N11O10, 793.9 g/mol, notation Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-OH: the acetylated-only form with a free acid end, not the amidated form. Created 16 May 2018; holds no literature, activity or toxicity sections; lists the six-residue synonym Ac-Thr-Lys-Pro-Arg-Gly-Pro. Retrieved 23 September 2026. https://pubchem.ncbi.nlm.nih.gov/compound/133082488
- FDA Global Substance Registration System, searches for "selank" (3 entries: Selank TS9JR8EP1G, Selank diacetate Q94Z9E92UU, N-acetyl selank J3PM702O93), "N-acetyl selank" (1) and "selank amidate" (0). Retrieved 23 September 2026. https://gsrs.ncats.nih.gov/
- Internet Archive copy of 8 October 2015 of the product page "N-Acetyl Selank Amidate" at an American research-chemical shop, the earliest capture of that page. It makes no claims of its own, refers readers to the encyclopaedia article on Selank, and states that the compound "has not been approved by the FDA and should be used for research purposes only." Retrieved 24 September 2026. Seller source, cited as evidence of what was on sale. Not linked.
- openFDA, drug/ndc. Search "selank": 9 bulk ingredient listings. NDC 73212-009 is named "Selank Acetate" but gives "N-ACETYL SELANK" as its active ingredient, marketed from 1 August 2020. "selank amidate" not found; drug/drugsfda and drug/label return no match for any acetylated or amidated form. Retrieved 23 September 2026. https://api.fda.gov/drug/ndc.json?search=active_ingredients.name:selank
- State Register of Medicines of the Russian Federation (ГРЛС), read through the mirror pharmcontrol.ru, source file of 22 September 2026. Search "селанк": 20 records, all Selank from AO INPZ Peptogen, including nasal drops under ЛСР-003338/09 of 30 April 2009 and ЛП-№(010951)-(РГ-RU) of 15 July 2025, all marked "Без рецепта" (without prescription). No record contains an acetyl or amide group. Retrieved 23 September 2026. https://www.pharmcontrol.ru/registry/drugs/?q=селанк
- World Anti-Doping Agency. The 2026 Prohibited List, in force from 1 January 2026, section S0, including "All prohibited substances in this class are Specified Substances." Full-text search for "selank" and "acetyl" returned no match. Retrieved 23 September 2026. https://www.wada-ama.org/en/prohibited-list
- Internet Archive copy of 26 June 2015 of the product page "N-Acetyl Selank" at the same shop, the earliest capture of that page. It claims the acetylated form is "much more stable" and "speeds up the transport across the blood brain barrier", without citing any study. Retrieved 24 September 2026. Seller source, cited as evidence of what is claimed. Not linked.
- FDA Global Substance Registration System. Substance J3PM702O93, N-ACETYL SELANK, full record. Described as "Selank with the N-terminus acetylated"; references a report of the French medicines regulator ANSM dated 17 February 2016, an import dated 28 April 2017 and a seller's product page, which is not reproduced here. No record exists for the amidated form. Retrieved 23 September 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/J3PM702O93
- European Medicines Agency, medicines output JSON report of centrally authorised human medicines (2,746 entries): "selank" 0, control "semaglutide" 10. Germany and the United Kingdom were not queried in a national database; the finding there is inferred from the absence of any approval, application or clinical trial worldwide. Retrieved 23 September 2026. https://www.ema.europa.eu/en/medicines
- CyberLeninka, Russian-language scientific library. Searches for "ацетил селанк" (5), "селанк амид" (5) and "N-acetyl selank" (3), all misses on checking; control "селанк" (160). Retrieved 23 September 2026. https://cyberleninka.ru/
- Wikidata. Search for "N-acetyl selank" (no entity); control "selank" (Q5810370). Retrieved 23 September 2026. https://www.wikidata.org/wiki/Q5810370
- PubChem patent records linked to CID 133082488: seven documents from a single applicant on nanoparticle delivery systems and gene editing (EP3554555A1, EP3781683A1, CA3045134A1, CA3138991A1, CN110582302A, IL267033B1, KR20240172763A). No study of the molecule. Retrieved 23 September 2026. https://pubchem.ncbi.nlm.nih.gov/compound/133082488#section=Patents
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, entry "Selank acetate (TP-7)", page as at 22 April 2026. Retrieved 23 September 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- AO INPZ Peptogen (2017). "Селанк стал безрецептурным препаратом" (Selank has become a non-prescription medicine), announcement of 2 August 2017, citing health ministry decision No. 20-3-4042618/ИД/ИЗМ. Retrieved 23 September 2026. https://peptogen.ru/sobitij/selank-bezretsepturnyy-preparat/
- DailyMed. Search for "selank": 0 labels, database as at 22 September 2026. Retrieved 23 September 2026. https://dailymed.nlm.nih.gov/dailymed/services/v2/spls.json?drug_name=selank
- Therapeutic Goods Administration, Poisons Standard 2026, full-text search: "selank" 0; controls BPC-157 3, Melanotan II 2. The register of therapeutic goods was not queried directly; unregistered medicines may not be supplied in Australia. Retrieved 23 September 2026. https://www.tga.gov.au/resources/artg
- Health Canada, Drug Product Database API. Ingredient and brand searches for "selank" (empty); control "semaglutide" (51 ingredient records). Retrieved 23 September 2026. https://health-products.canada.ca/api/drug/activeingredient/?lang=en&type=json&ingredientname=selank
- Swissmedic, extended list of authorised medicines with active ingredients. "selank" 0; control "semaglutid" 17. Retrieved 23 September 2026. https://www.swissmedic.ch/swissmedic/de/home/services/listen_neu.html
- RLS, Russian medicines database. Product information for Selank nasal drops 0.15 %, ЛП-№(010951)-(РГ-RU), last amended 15 July 2025; active substance given as the diacetate of Thr-Lys-Pro-Arg-Pro-Gly-Pro; dispensed without prescription. Retrieved 23 September 2026. https://www.rlsnet.ru/drugs/selank-36612
- Germany. Annex to the Anti-Doping Act, Federal Law Gazette 2023 I No. 67. Full-text search for "selank" and "tuftsin" returned no match. Checked 23 September 2026. https://www.gesetze-im-internet.de/antidopg/anlage.html
Cite this page
The searches behind this page were run on 23 and 24 September 2026. For a substance with almost no scientific record, the date on which those searches came back empty is part of the finding itself.
myPeptides Research & Editing. (2026). N-Acetyl Selank Amidate: what the studies show, status and safety. Version 1.0, 24 September 2026. myPeptides Peptide Register. Retrieved from https://mypep.app/peptides/n-acetyl-selank
How pages in this register are compiled and graded is described under methodology; the full register is at peptides.
| Version | Date | Change |
|---|---|---|
| 1.0 | 2026-09-24 | Initial publication |
Last verified: 24 September 2026. Next review: on the appearance of any study of the molecule, any register entry naming it, or any change to the Russian licence of Selank or to the anti-doping classification.